BioCentury
ARTICLE | Company News

China Medical gains rights to Can-Fite's ADORA3 agonists

August 10, 2018 6:27 AM UTC

CMS Medical Venture Investment Ltd. gained rights to develop and commercialize piclidenoson (CF101) and namodenoson (CF102) in Taiwan and China, including Hong Kong and Macau, from Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-A:CANF).

Can-Fite received $2 million up front and is eligible for $14 million in regulatory milestones and $58.5 million in sales milestones. Can-Fite is also eligible for double-digit royalties...